Myelodysplastic syndromes (MDS) are stem-cell malignancies most frequently seen among elderly patients, resulting in a high annual incidence of approximately 14,000 new cases per year. The incidence of MDS continues to increase as our population ages. About 30-40% of MDS cases progress to acute myeloid leukemia (AML) with poor prognosis. The order of events occurring in the progression from normal health to MDS to acute leukemia is unknown. We have discovered a new oncogene, SALL4B, which is expressed constitutively in human leukemia cell lines and in almost 100% of primary AML cells. We have shown that transgenic mice that overexpress SALL4B exhibit MDS- like features and, subsequently, AML transformation associated with selective expansion of granulocyte/macrophage progenitor cells (GMPs) and hematopoetic stem cells (HSCs). The hypothesis underlying this proposal has two research components. First, we theorize that aberrant expression of SALL4B immortalizes HSCs/HPCs through activation of Bmi-1. Second, we theorize that SALL4B acts in concert with RAS and promotes progression of MDS to AML by enhancing proliferation of HSCs/HPCs. To test our hypothesis, we are proposing three specific but complementary aims designed to permit in-depth analysis of our SALL4B mouse model and to illuminate the development of MDS and AML.
Specific Aim 1 focuses on determination of mechanisms leading to expansion of SALL4B-HSC/GMP associated with development of MDS and AML transformation.
Specific Aim 2 focuses on identification of the molecular pathway(s) that mediates MDS progression.
Specific Aim 3 focuses on cooperation of SALLB with second mutations in MDS progression. Our novel mouse model is ideal for investigating these diseases and gaining insight in the progression of MDS to fatal, late stage AML. The order and timing of oncogenic events involving MDS and MDS transformation are unknown and this is a major shortfall in our current understanding of these diseases. Our approach is innovative because it encompasses the role of a newly identified oncogene and a novel mouse model. Importantly, we expect to expand the body of knowledge surrounding MDS and MDS transformation consequently leading to the identification of novel therapeutic targets for treatment and intervention. Public Health Relevance Myelodysplastic syndrome (MDS) is, at present, incurable preleukemic disease occurring most frequently among the elderly with about 14,000 new cases per year in the USA. About 30-40% of these cases progress to acute myeloid leukemia (AML). With an urgent need to improve therapy in this group, it is critical to generate effective modeling systems (including mouse models) for investigating the genetic lesions commonly observed in MDS and AML. However, the precise molecular mechanisms whereby genetic changes induce the progression of MDS to AML remain poorly understood. The proposed research focuses on an innovative mouse model for studying MDS progression and AML transformation. We will also translate these studies into new diagnostic and prognostic tools for predicting those patients whose disease may progress to AML, which is most generally lethal to the patient.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL087948-06
Application #
8197798
Study Section
Hematopoiesis Study Section (HP)
Program Officer
Di Fronzo, Nancy L
Project Start
2007-12-14
Project End
2013-11-30
Budget Start
2011-12-01
Budget End
2013-11-30
Support Year
6
Fiscal Year
2012
Total Cost
$413,624
Indirect Cost
$150,169
Name
State University New York Stony Brook
Department
Pathology
Type
Schools of Medicine
DUNS #
804878247
City
Stony Brook
State
NY
Country
United States
Zip Code
11794
Chen, Shaohua; Liu, Sichu; Xu, Ling et al. (2013) The characteristic expression pattern of BMI-1 and SALL4 genes in placenta tissue and cord blood. Stem Cell Res Ther 4:49
Liao, Wenbin; Aguila, Jerell R; Yao, Yixin et al. (2013) Enhancing bone marrow regeneration by SALL4 protein. J Hematol Oncol 6:84
Liu, Li; Souto, Joseph; Liao, Wenbin et al. (2013) Histone lysine-specific demethylase 1 (LSD1) protein is involved in Sal-like protein 4 (SALL4)-mediated transcriptional repression in hematopoietic stem cells. J Biol Chem 288:34719-28
Yang, Jianchang; Corsello, Tyler R; Ma, Yupo (2012) Stem cell gene SALL4 suppresses transcription through recruitment of DNA methyltransferases. J Biol Chem 287:1996-2005
Yang, Jianchang; Liao, Wenbin; Ma, Yupo (2012) Role of SALL4 in hematopoiesis. Curr Opin Hematol 19:287-91
Lu, J; Ma, Y; Kong, N et al. (2011) Dissecting the role of SALL4, a newly identified stem cell factor, in chronic myelogenous leukemia. Leukemia 25:1211-3
Aguila, Jerell R; Liao, Wenbin; Yang, Jianchang et al. (2011) SALL4 is a robust stimulator for the expansion of hematopoietic stem cells. Blood 118:576-85
Xu, Dan; O, Teresa M; Shartava, Archil et al. (2011) Isolation, characterization, and in vitro propagation of infantile hemangioma stem cells and an in vivo mouse model. J Hematol Oncol 4:54
Yang, Jianchang; Aguila, Jerell R; Alipio, Zaida et al. (2011) Enhanced self-renewal of hematopoietic stem/progenitor cells mediated by the stem cell gene Sall4. J Hematol Oncol 4:38
Alipio, Zaida; Liao, Wenbin; Roemer, Elizabeth J et al. (2010) Reversal of hyperglycemia in diabetic mouse models using induced-pluripotent stem (iPS)-derived pancreatic beta-like cells. Proc Natl Acad Sci U S A 107:13426-31

Showing the most recent 10 out of 17 publications